Navigation Links
Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing
Date:2/12/2008

FRANKLIN, Mass., Feb. 12 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a specialty pharmaceuticals and diagnostics company, announced today that it had completed an approximately $2.3 million private financing with Montaur Capital through Platinum Long Term Growth VII, LLC and certain other select institutional and strategic investors of senior unsecured convertible notes and warrants.

The $2,292,459 in aggregate principal amount of Senior Convertible Notes to be issued in the financing will bear interest annually at a rate of 8.0% per annum and will provide investors with the right to convert principal into shares of Echo Therapeutics common stock at $1.35 per share. The conversion price is subject to weighted average anti-dilution protection, excluding certain customary exceptions. The notes have a three-year term and Echo may elect to make payments of interest in cash, additional notes, or stock.

Additionally, the investors received warrants to purchase 849,058 shares of common stock at an exercise price of $1.69 per share for a term of five years. The warrants provide for full anti-dilution protection to the holders and allow for cashless exercise.

In connection with the financing, certain holders of Echo's Senior Promissory Bridge Notes, dated as of September 14, 2007, exchanged their Bridge Notes at 120% of the outstanding principal and interest of the Bridge Note as payment toward the purchase price of the Senior Convertible Notes purchased by such holders. Accordingly, Echo issued notes in the financing in the aggregate principal balance of $1,592,459 to the former holders of the Bridge Notes upon their surrender of the Bridge Notes, and Echo received gross cash proceeds in the amount of $700,000 in connection with the financing.

Echo expects to use the net proceeds from the offering for product development, working capital and general corporate purposes.

The securities issued in the financing have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States in the absence of an effective registration statement or an exemption from the registration requirements under the Securities Act. This notice does not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.

About Echo Therapeutics

Echo Therapeutics is a platform-enabled specialty pharmaceuticals and diabetes management company. Echo's Symphony(TM) CTGM System is a new needle- free, wireless, continuous transdermal glucose monitoring system focused on changing the paradigm of invasive, episodic glucose testing in diabetes home use and hospital critical care settings. Echo's patented AzoneTS(TM) transdermal drug delivery technology is focused on building a pipeline of proprietary reformulations of specialty pharmaceutical products previously approved by the U.S. Food and Drug Administration (FDA). Echo is developing most of its AzoneTS pipeline in accordance with the FDA's Section 505(b)(2) guidelines. Durhalieve(TM), Echo's lead AzoneTS drug candidate, is an advanced topical reformulation of triamcinolone acetonide for treatment of corticosteroid responsive dermatoses. Echo has submitted its Durhalieve New Drug Application (NDA) to the FDA.

Forward-Looking Statements

This press release contains forward-looking information that involves risks and uncertainties, including statements regarding Echo's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding Echo's offering of convertible senior notes. Factors that could adversely affect Echo's business and prospects are described in Echo's filings with the Securities and Exchange Commission. Echo expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Echo's expectations or any change in events, conditions or circumstances on which any such statement is based.

Investor Relations Contacts:

Patrick T. Mooney, M.D., CEO

Echo Therapeutics, Inc.

508-530-0329

Lilian Stern

Stern Investor Relations

212-362-1200


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Transition Therapeutics Announces Second Quarter Fiscal 2008 Financial Results
2. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
3. Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors
4. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2008 Financial Results on Tuesday, February 12, 2008 at 5:00 P.M. EST
5. Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP
6. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
7. Prime Therapeutics Becomes First PBM to Join the Center for Health Value Innovation
8. Reckitt Benckiser Completes Acquisition of Adams Respiratory Therapeutics, Inc.
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
10. Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing
11. Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... ... May 30, 2016 , ... Zane Benefits, the leader ... an original infographic, " Health Benefits Reimbursement Compliance Timeline ." , The ... complies with various federal regulations and reforms. , Navigating the new health reforms ...
(Date:5/29/2016)... (PRWEB) , ... May 29, 2016 , ... "With 30 ... let's the user control the style of their project," said Christina Austin - CEO ... 30 self-animating web-themed intros created exclusively for use in Final Cut Pro X. Pixel ...
(Date:5/28/2016)... ... , ... In a part of the city where’s it’s easy to spot the neon lights ... is hoping to attract diners with a taste for real food. , On May ... to Cornerstone Grill, an urban casual restaurant focusing on dishes made by hand with wholesome, ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses and professionals in ... lights on the variety of topics detailing why we appreciate nurses in so many ... career has gone from being in a major recession to one of the hottest ...
(Date:5/27/2016)... ... , ... Beleza Medspa has initiated a new program to assist ... first time that Coolsculpting is being used for for more than just cosmetic purposes. ... meet the prescribed body-fat standard, measured by the circumference-based tape method. The tape-test ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... -- Hutchison China MediTech (Chi-Med) (HCM) ... highly lucrative global oncology and immunology markets. HCM ... or best-in-class tyrosine kinase inhibitor (TKI) drugs, some ... HCM,s profitable Chinese healthcare business continues to benefit ... of the mid-to-late-stage pipeline during 2016-17 (including US ...
(Date:5/26/2016)... A key trend that will ... of new treatments. Cardax, a development stage life sciences ... therapy is expected to fulfil large unmet medical needs ... studies to develop new treatments for osteoarthritis. One such ... in osteoarthritis are being investigated, and early trials of ...
(Date:5/25/2016)... According to a new market ... 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application ... Manufacturers, Hospitals/ Clinics) - Forecast to 2021", published by ... for the forecast period of 2016 to 2021. This ... 2021 from USD 117.3 Million in 2016, at a ...
Breaking Medicine Technology: